Scientific Background and Reference Sources
ACOG. (2020, October 9). Updated Guidelines for Management of Cervical Cancer Screening Abnormalities. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/10/updated-guidelines-for-management-of-cervical-cancer-screening-abnormalities
ACOG. (2021, April 12). Updated Cervical Cancer Screening Guidelines. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
ACS. (2023, January 12, 2023). Key Statistics for Cervical Cancer. American Cancer Society, Inc. Retrieved 06/05/2023 from https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html
ASCO. (2022). Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update. https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/practice-patients/documents/2022-Cervical-Cancer-Secondary-Prev-RS-Summary-Table.pdf
Bonde, J. H., Sandri, M. T., Gary, D. S., & Andrews, J. C. (2020). Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review. J Low Genit Tract Dis, 24(1), 1-13. https://doi.org/10.1097/lgt.0000000000000494
Chen, H. C., Schiffman, M., Lin, C. Y., Pan, M. H., You, S. L., Chuang, L. C., Hsieh, C. Y., Liaw, K. L., Hsing, A. W., & Chen, C. J. (2011). Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst, 103(18), 1387-1396. https://doi.org/10.1093/jnci/djr283
Dahlstrom, L. A., Ylitalo, N., Sundstrom, K., Palmgren, J., Ploner, A., Eloranta, S., Sanjeevi, C. B., Andersson, S., Rohan, T., Dillner, J., Adami, H. O., & Sparen, P. (2010). Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer, 127(8), 1923-1930. https://doi.org/10.1002/ijc.25408
Dilley, S., Huh, W., Blechter, B., & Rositch, A. F. (2021). It's time to re-evaluate cervical Cancer screening after age 65. Gynecol Oncol, 162(1), 200-202. https://doi.org/10.1016/j.ygyno.2021.04.027
EASC. (2023). Guidelines Version 12.0. https://www.eacsociety.org/guidelines/eacs-guidelines/
FDA. (2018). BD ONCLARITY HPV ASSAY. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=391601
FDA. (2023a). BD ONCLARITY HPV ASSAY. U.S. Food & Drug Administration. Retrieved 06/05/2023 from https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=391601
FDA. (2023b). Cobas HPV For Use On The Cobas 6800/8800 Systems. https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=448383
FDA. (2023c). PMA Monthly approvals from 7/1/2018 to 7/31/2018. Food and Drug Agency. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=409848
Feldman, S., & Crum, C. (2023, May 2, 2022). Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing. https://www.uptodate.com/contents/cervical-cancerscreening-tests-techniques-for-cervical-cytology-and-human-papillomavirus-testing
Feldman, S., Goodman, A., & Peipert, J. (2024, May 23, 2023). Screening for cervical cancer in resource-rich settings. https://www.uptodate.com/contents/screening-for-cervical-cancer-in-resourcerich-settings
Fontham, E. T. H., Wolf, A. M. D., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. T., Walter, L. C., Kim, J. J., Andrews, K. S., DeSantis, C. E., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., Wender, R. C., & Smith, R. A. (2020). Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin, 70(5), 321-346. https://doi.org/10.3322/caac.21628
Huh, W. K., Ault, K. A., Chelmow, D., Davey, D. D., Goulart, R. A., Garcia, F. A., Kinney, W. K., Massad, L. S., Mayeaux, E. J., Saslow, D., Schiffman, M., Wentzensen, N., Lawson, H. W., & Einstein, M. H. (2015). Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis, 19(2), 91-96. https://doi.org/10.1097/lgt.0000000000000103
Marchand, L., Mundt, M., Klein, G., & Agarwal, S. C. (2005). Optimal collection technique and devices for a quality pap smear. Wmj, 104(6), 51-55.
Massad, L. S. (2018). Replacing the Pap Test With Screening Based on Human Papillomavirus Assays. Jama, 320(1), 35-37. https://doi.org/10.1001/jama.2018.7911
Melnikow, J., Henderson, J. T., Burda, B. U., Senger, C. A., Durbin, S., & Weyrich, M. S. (2018). Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Jama, 320(7), 687-705. https://doi.org/10.1001/jama.2018.10400
Mendez, K., Romaguera, J., Ortiz, A. P., Lopez, M., Steinau, M., & Unger, E. R. (2014). Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. Int J Gynaecol Obstet, 124(2), 151-155. https://doi.org/10.1016/j.ijgo.2013.07.036
Moscicki, A. B., Flowers, L., Huchko, M. J., Long, M. E., MacLaughlin, K. L., Murphy, J., Spiryda, L. B., & Gold, M. A. (2019). Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. J Low Genit Tract Dis, 23(2), 87-101. https://doi.org/10.1097/lgt.0000000000000468
NCCN. (2024, April 28, 2023). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) - Cervical Cancer Version 3.2024.https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
NCI. (2024, April 21, 2023). Cervical Cancer Screening (PDQ®)–Health Professional Version. National Institutes of Health. https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq
Ogilvie, G. S., van Niekerk, D., Krajden, M., Smith, L. W., Cook, D., Gondara, L., Ceballos, K., Quinlan, D., Lee, M., Martin, R. E., Gentile, L., Peacock, S., Stuart, G. C. E., Franco, E. L., & Coldman, A. J. (2018). Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Jama, 320(1), 43-52. https://doi.org/10.1001/jama.2018.7464
Pathak, N., Dodds, J., Zamora, J., & Khan, K. (2014). Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. Bmj, 349, g5264. https://doi.org/10.1136/bmj.g5264
Pry, J. M., Manasyan, A., Kapambwe, S., Taghavi, K., Duran-Frigola, M., Mwanahamuntu, M., Sikazwe, I., Matambo, J., Mubita, J., Lishimpi, K., Malama, K., & Bolton Moore, C. (2021). Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study. Lancet Glob Health, 9(6), e832-e840. https://doi.org/10.1016/s2214-109x(21)00062-0
Rice, S. L., Editor. (2018, August 2018). Cobas HPV test approved for first-line screening using SurePath preservative fluid. CAP Today.
Sabeena, S., Kuriakose, S., Binesh, D., Abdulmajeed, J., Dsouza, G., Ramachandran, A., Vijaykumar, B., Aswathyraj, S., Devadiga, S., Ravishankar, N., & Arunkumar, G. (2019). The Utility of Urine-Based Sampling for Cervical Cancer Screening in Low-Resource Settings. Asian Pac J Cancer Prev, 20(8), 2409-2413. https://doi.org/10.31557/apjcp.2019.20.8.2409
Sasieni, P., Castanon, A., & Cuzick, J. (2009). Screening and adenocarcinoma of the cervix. Int J Cancer, 125(3), 525-529. https://doi.org/10.1002/ijc.24410
USPSTF. (2018). Screening for Cervical Cancer: US Preventive Services Task Force Recommendation StatementUSPSTF Recommendation: Screening for Cervical CancerUSPSTF Recommendation: Screening for Cervical Cancer. Jama, 320(7), 674-686. https://doi.org/10.1001/jama.2018.10897
William R Robinson. (2024a, 01/19/2023). Screening for cervical cancer in patients with HIV infection and other immunocompromised states. https://www.uptodate.com/contents/screening-for-cervicalcancer-in-patients-with-hiv-infection-and-other-immunocompromised-states
William R Robinson. (2024b, 05/23/2023). Screening for Cervical Cancer in Resource-Risk Settings. https://www.uptodate.com/contents/screening-for-cervical-cancer-in-resource-rich-settings
Winer, R. L., Lin, J., Anderson, M. L., Tiro, J. A., Green, B. B., Gao, H., Meenan, R. T., Hansen, K., Sparks, A., & Buist, D. S. M. (2023). Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial. Jama, 330(20), 1971-1981. https://doi.org/10.1001/jama.2023.21471
Specialty Matched Consultant Advisory Panel 3/2020
Medical Director Review 10/2022
Medical Director Review 10/2023
Medical Director Review 10/2024